Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting a price target of $478.
The analyst based the optimistic rating on the positive potential of the company’s kidney franchise, stating that its innovative approach with povetacicept employing a dual BAFF/APRIL blockade is considered to offer lasting and more profound disease control in comparison to single-pathway treatments.
Early data supports this by showing considerable proteinuria reduction and stabilization of eGFR. According to Fein, this points towards a multi-billion-dollar opportunity and paves the way for it to become a first-in-class treatment.
He also cited Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) strategic expansion into primary membranous nephropathy (PMN), as the condition does not have any approved therapies, and this positions povetacicept as a potential first-in-class option.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops medicines for rare serious diseases. Its four approved medicines treat cystic fibrosis (CF), and one approved therapy treats severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company’s product pipeline includes clinical-stage programs for various disorders, including TDT, SCD, CF, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency.
While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
